November 20, 2009 08:00 ET

OPTIMIZERx Engages Beringea LLC as Advising Partner for Growth

ROCHESTER, MI--(Marketwire - November 20, 2009) - OPTIMIZERx Corporation (OTCBB: OPRX) has engaged Beringea LLC, an investment banking and private equity firm, to assist in financial planning and strategic positioning for the company's continued growth.

"Beringea specializes in advising clients who are seeking to execute strategic transactions or find private financing," said David Lester, CEO, OPRIMIZERx. "As we continue to position OPTIMIZERx's growth within the healthcare marketplace we look to Beringea to be a strategic advisory partner for both growth and financial stability."

"Beringea's transaction advisory team has a deep expertise in the healthcare sector and is excited to share OPTIMIZERx's value proposition with the market," said David Eberly, Beringea's senior managing director and co-founder. "OPTIMIZERx's ability to simplify complex medical processes like prescription sampling administration and distribution represents real cost saving opportunities to the industry and makes it an attractive player in the healthcare IT space."

OPTIMIZERx recently announced the launch of SampleMD™ -- a new, downloadable virtual "drug sample cabinet" that allows doctors and staff to print or electronically send sample vouchers and co-pay coupons right to pharmacies directly from their desktops. To learn more about SampleMD visit:

About OPTIMIZERx Corporation

OPTIMIZERx provides unique platforms to help patients better afford and comply to their medicines and healthcare products while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company's patient support website,, and its permanent subscriber base, continue to grow each month and is quickly becoming the preferred way to access branded prescription savings and support programs. Additionally, OPTIMIZERx has developed OFFERx™ and ADHERxE™ to allow a more streamlined, effective way to create, promote and manage new trial or co-pay programs on behalf of brand-name pharmaceuticals and health care products.


This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:
    David Lester